Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, New York.
Mount Sinai Beth Israel, New York, New York.
J Clin Pharm Ther. 2020 Aug;45(4):845-847. doi: 10.1111/jcpt.13179. Epub 2020 Jun 1.
Haemoptysis is a major complication of cystic fibrosis (CF) and is associated with pulmonary exacerbations and admission to the hospital. The US CF Pulmonary Foundation guidelines fail to reach consensus on haemoptysis treatment regarding pharmacotherapy options.
We describe a case in which systemic tranexamic acid was utilized to treat haemoptysis in a CF adult patient who was experiencing progressively worsening haemoptysis despite numerous bronchial artery embolization procedures.
The use of antifibrinolytic agents may be of potential benefit in refractory haemoptysis episodes in adult CF patients.
咯血是囊性纤维化（CF）的主要并发症，与肺部恶化和住院有关。美国 CF 基金会的指南未能就咯血的药物治疗选择达成共识。
我们描述了一例 CF 成年患者咯血的病例，尽管多次支气管动脉栓塞术，但患者咯血仍逐渐加重，因此使用了全身性氨甲环酸进行治疗。
抗纤维蛋白溶解剂的使用可能对成年 CF 患者难治性咯血发作有益。
